
[Federal Register: September 23, 2010 (Volume 75, Number 184)]
[Notices]               
[Page 57967-57968]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23se10-73]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0001]

 
Science Advisory Board to the National Center for Toxicological 
Research Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Science Advisory Board (SAB) to the National 
Center for Toxicological Research (NCTR).
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on October 19, 2010, from 
8:15 a.m. to 5:30 p.m. and on October 20, 2010, from 8:30 a.m. to 1 
p.m.
    Location: National Center for Toxicological Research, 3900 NCTR 
Dr., Jefferson, AR 72079, Conference Room B-12.
    Contact Person: Margaret Miller, NCTR, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 2208, Silver 
Spring, MD, 20993-0002, 301-796-8890, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 301-451-2559. Please call the Information Line for up-to-
date information on this meeting. A notice in the Federal Register 
about last minute modifications that impact a previously announced 
advisory committee meeting cannot always be published quickly enough to 
provide timely notice. Therefore, you should always check the agency's 
Web site and call the appropriate advisory committee hot line/phone 
line to learn about possible modifications before coming to the 
meeting.
    Agenda: On October 19, 2010, NCTR Director will provide a Center-
wide update on scientific endeavors and discuss prioritization, 
alignment, and the strategic focus of NCTR. The SAB will be presented 
with updates from each of the NCTR divisions on their individual 
accomplishments and future research plans based on the major items 
identified in the last subcommittee review. The report of the 
subcommittee review of the Division of Neurotoxicology will be 
presented for discussion and adoption by the full Board. On October 20, 
2010, the SAB will be presented with and discuss the NCTR Strategic 
Focus and future direction, and the need for research and potential 
collaborations. A discussion will be conducted on the organization of 
the SAB, site visits and SAB assignments.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: On October 19, 2010, from 8:15 a.m. to 5:30 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before October 18, 2010. Oral presentations from the public will be 
scheduled between approximately 12 p.m. to 1 p.m. Those desiring to 
make formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before October 8, 2010. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by October 11, 2010.
    Closed Committee Deliberations: On October 20, 2010, from 12 p.m. 
to 1 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted

[[Page 57968]]

invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the 
meeting will be closed to permit discussion of information concerning 
individuals associated with the research programs at NCTR.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Margaret Miller at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at: http://www.fda.gov/
AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: September 17, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-23843 Filed 9-22-10; 8:45 am]
BILLING CODE 4160-01-S

